Zinc levels in serum during subcutaneous interleukin-2 immunotherapy of cancer

Int J Biol Markers. 1995 Apr-Jun;10(2):124-5. doi: 10.1177/172460089501000213.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Aged
  • Biomarkers
  • Carcinoma, Renal Cell / blood*
  • Carcinoma, Renal Cell / secondary
  • Carcinoma, Renal Cell / therapy
  • Circadian Rhythm / drug effects
  • Female
  • Humans
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / adverse effects
  • Immunologic Factors / pharmacology
  • Immunotherapy*
  • Injections, Subcutaneous
  • Interleukin-2 / administration & dosage*
  • Interleukin-2 / adverse effects
  • Interleukin-2 / pharmacology
  • Kidney Neoplasms / blood*
  • Kidney Neoplasms / therapy
  • Male
  • Melatonin / metabolism
  • Middle Aged
  • Pineal Gland / drug effects
  • Pineal Gland / metabolism
  • Zinc / blood*
  • Zinc / deficiency

Substances

  • Biomarkers
  • Immunologic Factors
  • Interleukin-2
  • Zinc
  • Melatonin